NC71
NOTICE OF CANCELLATION SEC. 71 E-MAILED
10/02/2026
Voltar para busca
Dado oficial do USPTO
OPTHEA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
35
Atualização mais recente
03/03/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
07/12/2016
Data de registro
29/05/2018
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
10/02/2026
Última transação
03/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
SOUTH YARRA VIC, AU
Examinador
THOMAS, JULIE
Localização atual
Historical data usage
Titulares e representantes
Titulares
Opthea Limited
Opthea Limited
Representantes
Richard M. LaBarge Marshall, Gerstein & Borun LLP
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Biological preparations for pharmaceutical purposes for the treatment of ophthalmic conditions; Chemical preparations for pharmaceutical purposes for the treatment of ophthalmic conditions; Chemical productssugarsproteins and nucleic acids for pharmaceutical use for the treatment of ophthalmic conditions; Chemicals for pharmaceutical use for the treatment of ophthalmic conditions; Pharmaceutical compositions for the treatment of ophthalmic conditions; Pharmaceutical creams for the treatment of ophthalmic conditions; Pharmaceutical drugs for the treatment of ophthalmic conditions; Pharmaceutical preparations for the treatment of ophthalmic conditions ; Pharmaceutical preparations for animals for the treatment of ophthalmic conditions; Pharmaceutical preparations for human use for the treatment of ophthalmic conditions; Pharmaceutical preparations for personal use for the treatment of ophthalmic conditions; Pharmaceutical preparations for veterinary use for the treatment of ophthalmic conditions; Pharmaceutical products for the treatment of ophthalmic conditions; Pharmaceutical products for use by humans for the treatment of ophthalmic conditions; Pharmaceutical substances for the treatment of ophthalmic conditions; Veterinary medicaments for the treatment of ophthalmic conditions; Veterinary preparations for the treatment of ophthalmic conditions; Veterinary products for the treatment of ophthalmic conditions; Biological preparations for medical purposes for the treatment of ophthalmic conditions; Biological preparations for use in biotechnology for the treatment of ophthalmic conditions; Biological preparations for use in cell culturesnamely in culture media for cultivating humananimalplant or microorganism cells for medical use; Biological preparations for veterinary purposes for the treatment of ophthalmic conditions; Biological products for medical usenamely for the treatment of ophthalmic conditions; Biological reagents for use in molecular biology for medical use; Biological substances for medical usebiologicsantibodiesmonoclonal antibodiescells and cellular tissues for medical usenamely for the treatment of ophthalmic conditions; Biological tissue cultures for medical purposes; Biological tissue cultures for veterinary purposes; Chemical productsbiologicssugarsproteinsnucleic acids and pharmaceuticals for use in biology for medical or veterinary usenamely for the diagnosis of ophthalmic conditionsorfor the treatment of ophthalmic conditions; Therapeutic biological productsbiologicsantibodiesmonoclonal antibodiescells and cellular tissues for medical usenamely for the treatment of ophthalmic conditions; Medical preparations for the treatment of ophthalmic conditions; Substances for use in genetic probe assay kits for medical usemedical diagnostic reagents and assays for testing body fluids; Substances for veterinary use produced by genetic engineeringgenetically engineered tissues for transplant purposes; Cultures of cell media for medical use; Cultures of cell media for veterinary purposes; Chemical products for medical or veterinary laboratory usebiologicssugarsproteinsnucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditionsorfor the treatment of ophthalmic conditions; Chemical preparations for medical analysis purposesbiologicssugarsproteinsnucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical preparations for medical purposes for the diagnosis of ophthalmic conditionsorfor the treatment of ophthalmic conditions; Chemical preparations for veterinary purposesbiologicssugarsproteinsnucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditionsorfor the treatment of ophthalmic conditions; Chemical products for analysis for medical purposesbiologicssugarsproteinsnucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical products for analysis for veterinary purposesbiologicssugarsproteinsnucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical products for biotechnological purposes for medical usesbiologicssugarsproteinsnucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditionsorfor the treatment of ophthalmic conditions; Chemical products for biotechnological purposes for veterinary usebiologicssugarsproteinsnucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditionsorfor the treatment of ophthalmic conditions; Chemical products for medical or veterinary diagnostic purposesbiologicssugarsproteinsnucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical products for medical diagnostic usebiologicssugarsproteinsnucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical products for veterinary diagnostic usebiologicssugarsproteinsnucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical products for medical usebiologicssugarsproteinsnucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditionsorfor the treatment of ophthalmic conditions; Chemical products for use in medical sciencebiologicssugarsproteinsnucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditionsorfor the treatment of ophthalmic conditions; Chemical products for use in science for medical or veterinary purposesbiologicssugarsproteinsnucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditionsorfor the treatment of ophthalmic conditions; Chemicals for use in medical and veterinary analysisbiologicssugarsproteinsnucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions
Classe 42
Advisory services relating to scientific research; Laboratory servicesscientific research or analysis in the field of ophthalmology; Management of scientific research projects; Medical research and scientific research for medical purposes; Preparation of reports relating to scientific research; Preparation of scientific reports; Providing informationincluding onlineabout scientific and technological services and research and design relating theretonamely for scientific researchanalyses and testing in the field of ophthalmology; Provision of information relating to scientific research; Provision of scientific information in the field of ophthalmology; Scientific advisory services in the field of ophthalmology; Scientific analysis in the field of ophthalmology; Technical analysis for research and testing in the field of ophthalmology; Scientific and technological services namely for scientific researchanalysis and testing in the field of ophthalmology; Scientific consultancy relating to ophthalmic conditions; Scientific laboratory services; Scientific research; Scientific research in the field of pharmacy; Scientific research into the development of new products; Scientific research relating to bacteriology; Scientific research relating to biology; Scientific research relating to chemical products; Scientific research relating to chemistry; Scientific research relating to genetics; Scientific testing services in the field of ophthalmology; Bacteriological research; Biochemistry research services; Biological research; Biotechnological research; Biotechnology research; Chemical research; Chemical technological research; Genetic research; Laboratory research; Medical research; Pharmaceutical research services; Providing informationincluding onlineabout industrial analysis and research services namely for scientific researchanalyses and testing in the field of ophthalmology; Provision of medicalveterinarybiological and pharmaceutical research services in the field of ophthalmology; Research and development of new products for others; Research and development of products; Research into the development of new products; Research laboratories in the field of ophthalmology; Research relating to bacteriology; Research relating to biotechnology; Research relating to chemicals; Research relating to chemistry; Research relating to medicine; Research relating to molecular sciences; Research relating to pharmaceuticals; Research relating to science; Research to develop new products; Services for assessing the efficiency of pharmaceuticals namely pharmaceutical product evaluation; Services for assessing the safety of pharmaceuticalsnamely testinginspection or research of pharmaceuticals; Chemical analysis; Laboratory analysis in the field of ophthalmology; Analysis of tissues for medical research; Design of medical apparatus; Medical laboratory services; Analytical laboratory servicesnamely analysis of tissue samples or bodily fluids for diagnostic purposes; Chemical laboratory services; Laboratory testing servicesnamely testing of tissue samples or bodily fluids for diagnostic purposes; Veterinary laboratory services; Information in the field of chemical research; Testing of chemicals
Publicações
Histórico de despachos e eventos da marca no USPTO.
35 publicações encontradas
C71T
CANCELLED SECTION 71
10/02/2026
PR71
POST REGISTRATION ACTION MAILED - SEC.71
28/07/2025
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
07/07/2025
PR71
POST REGISTRATION ACTION MAILED - SEC.71
04/01/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
26/12/2024
ES71
TEAS SECTION 71 RECEIVED
22/05/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
29/05/2023
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
15/12/2022
RHRD
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
03/12/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/01/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
28/09/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/09/2018
FIMP
FINAL DISPOSITION PROCESSED
12/09/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
29/08/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
29/05/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
13/03/2018
PUBO
PUBLISHED FOR OPPOSITION
13/03/2018
GPNX
NOTIFICATION PROCESSED BY IB
09/03/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
21/02/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
21/02/2018
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
21/02/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/02/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/01/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/01/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/01/2018
RFNT
REFUSAL PROCESSED BY IB
28/07/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/07/2017
RFRR
REFUSAL PROCESSED BY MPU
06/07/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
30/06/2017
CNRT
NON-FINAL ACTION WRITTEN
29/06/2017
MAFR
APPLICATION FILING RECEIPT MAILED
27/06/2017
DOCK
ASSIGNED TO EXAMINER
23/06/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
23/06/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
22/06/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace OPTHEA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.